Associations between Genetic Polymorphisms of Epidermal Growth Factor Receptor (EGFR) and survival of colorectal cancer (crc) patients treated with 5-fluorouracil-based chemotherapy

Ching Yu Lai, Fung Chang Sung, Ling Ling Hsieh, Reiping Tang, Hung Yi Chiou, Fang Yang Wu, Chih Ching Yeh

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Purpose. This retrospective cohort study investigated the association between epidermal growth factor receptor (EGFR) polymorphisms and clinical outcomes in colorectal cancer (CRC) patients treated with 5-fluorouracil (5-FU)-based chemotherapy. Methods. We genotyped 3 EGFR polymorphisms including R497K, G-216T, and the (CA)n repeat, among 499 histologically confirmed CRC patients who had received 5-FU-based chemotherapy after surgery between 1995 and 2001. Survival analyses of EGFR polymorphisms were performed by the log rank test and Kaplan-Meier curves. We used the Cox proportional hazard model to evaluate the association between EGFR genotypes and clinical outcomes. Stratification analysis by gender, tumor stage, and subsite were also carried out. Results. CRC patients with the EGFR (CA)n L/L genotype compared to those with the S/S?S/L genotype had a significantly better overall survival (L, C20 repeats; S,\20 repeats) (hazard ratio (HR) 0.74; 95 % confidence interval (CI) 0.57-0.95), particularly for patients who were male (HR 0.63; 95 % CI 0.44-0.90), who had stage IV disease (HR 0.70; 95 % CI 0.49-0.99), and who had rectal cancer (HR 0.62; 95 % CI 0.42-0.92). Better survival was prominent among patients with the combined genotypes of EGFR (CA)n L/L, G-216T G/G, and R497K K/K (HR 0.51; 95 % CI 0.30-0.87), compared to those with the most common genotypes of the EGFR (CA)n S allele, G-216T G/G, and R497K R allele. Conclusions. EGFR polymorphisms can serve as prognostic predictors for CRC patients receiving 5-FU-based chemotherapy.

Original languageEnglish
Pages (from-to)S599-S606
Number of pages8
JournalAnnals of Surgical Oncology
Volume20
Issue number3 SUPPL.
DOIs
Publication statusPublished - 2013

Fingerprint

Genetic Polymorphisms
Epidermal Growth Factor Receptor
Fluorouracil
Colorectal Neoplasms
Drug Therapy
Survival
Genotype
Confidence Intervals
Alleles
Kaplan-Meier Estimate
Rectal Neoplasms
Survival Analysis
Proportional Hazards Models
Cohort Studies
Retrospective Studies

Keywords

  • Colorectal Neoplasms
  • genetic polymorphism
  • survival rate

ASJC Scopus subject areas

  • Surgery
  • Oncology
  • Medicine(all)

Cite this

Associations between Genetic Polymorphisms of Epidermal Growth Factor Receptor (EGFR) and survival of colorectal cancer (crc) patients treated with 5-fluorouracil-based chemotherapy. / Lai, Ching Yu; Sung, Fung Chang; Hsieh, Ling Ling; Tang, Reiping; Chiou, Hung Yi; Wu, Fang Yang; Yeh, Chih Ching.

In: Annals of Surgical Oncology, Vol. 20, No. 3 SUPPL., 2013, p. S599-S606.

Research output: Contribution to journalArticle

@article{eb410019220d4c3086d12c8e75d9cd4f,
title = "Associations between Genetic Polymorphisms of Epidermal Growth Factor Receptor (EGFR) and survival of colorectal cancer (crc) patients treated with 5-fluorouracil-based chemotherapy",
abstract = "Purpose. This retrospective cohort study investigated the association between epidermal growth factor receptor (EGFR) polymorphisms and clinical outcomes in colorectal cancer (CRC) patients treated with 5-fluorouracil (5-FU)-based chemotherapy. Methods. We genotyped 3 EGFR polymorphisms including R497K, G-216T, and the (CA)n repeat, among 499 histologically confirmed CRC patients who had received 5-FU-based chemotherapy after surgery between 1995 and 2001. Survival analyses of EGFR polymorphisms were performed by the log rank test and Kaplan-Meier curves. We used the Cox proportional hazard model to evaluate the association between EGFR genotypes and clinical outcomes. Stratification analysis by gender, tumor stage, and subsite were also carried out. Results. CRC patients with the EGFR (CA)n L/L genotype compared to those with the S/S?S/L genotype had a significantly better overall survival (L, C20 repeats; S,\20 repeats) (hazard ratio (HR) 0.74; 95 {\%} confidence interval (CI) 0.57-0.95), particularly for patients who were male (HR 0.63; 95 {\%} CI 0.44-0.90), who had stage IV disease (HR 0.70; 95 {\%} CI 0.49-0.99), and who had rectal cancer (HR 0.62; 95 {\%} CI 0.42-0.92). Better survival was prominent among patients with the combined genotypes of EGFR (CA)n L/L, G-216T G/G, and R497K K/K (HR 0.51; 95 {\%} CI 0.30-0.87), compared to those with the most common genotypes of the EGFR (CA)n S allele, G-216T G/G, and R497K R allele. Conclusions. EGFR polymorphisms can serve as prognostic predictors for CRC patients receiving 5-FU-based chemotherapy.",
keywords = "Colorectal Neoplasms, genetic polymorphism, survival rate, Colorectal Neoplasms, genetic polymorphism, survival rate",
author = "Lai, {Ching Yu} and Sung, {Fung Chang} and Hsieh, {Ling Ling} and Reiping Tang and Chiou, {Hung Yi} and Wu, {Fang Yang} and Yeh, {Chih Ching}",
year = "2013",
doi = "10.1245/s10434-013-3069-4",
language = "English",
volume = "20",
pages = "S599--S606",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
publisher = "Springer New York",
number = "3 SUPPL.",

}

TY - JOUR

T1 - Associations between Genetic Polymorphisms of Epidermal Growth Factor Receptor (EGFR) and survival of colorectal cancer (crc) patients treated with 5-fluorouracil-based chemotherapy

AU - Lai, Ching Yu

AU - Sung, Fung Chang

AU - Hsieh, Ling Ling

AU - Tang, Reiping

AU - Chiou, Hung Yi

AU - Wu, Fang Yang

AU - Yeh, Chih Ching

PY - 2013

Y1 - 2013

N2 - Purpose. This retrospective cohort study investigated the association between epidermal growth factor receptor (EGFR) polymorphisms and clinical outcomes in colorectal cancer (CRC) patients treated with 5-fluorouracil (5-FU)-based chemotherapy. Methods. We genotyped 3 EGFR polymorphisms including R497K, G-216T, and the (CA)n repeat, among 499 histologically confirmed CRC patients who had received 5-FU-based chemotherapy after surgery between 1995 and 2001. Survival analyses of EGFR polymorphisms were performed by the log rank test and Kaplan-Meier curves. We used the Cox proportional hazard model to evaluate the association between EGFR genotypes and clinical outcomes. Stratification analysis by gender, tumor stage, and subsite were also carried out. Results. CRC patients with the EGFR (CA)n L/L genotype compared to those with the S/S?S/L genotype had a significantly better overall survival (L, C20 repeats; S,\20 repeats) (hazard ratio (HR) 0.74; 95 % confidence interval (CI) 0.57-0.95), particularly for patients who were male (HR 0.63; 95 % CI 0.44-0.90), who had stage IV disease (HR 0.70; 95 % CI 0.49-0.99), and who had rectal cancer (HR 0.62; 95 % CI 0.42-0.92). Better survival was prominent among patients with the combined genotypes of EGFR (CA)n L/L, G-216T G/G, and R497K K/K (HR 0.51; 95 % CI 0.30-0.87), compared to those with the most common genotypes of the EGFR (CA)n S allele, G-216T G/G, and R497K R allele. Conclusions. EGFR polymorphisms can serve as prognostic predictors for CRC patients receiving 5-FU-based chemotherapy.

AB - Purpose. This retrospective cohort study investigated the association between epidermal growth factor receptor (EGFR) polymorphisms and clinical outcomes in colorectal cancer (CRC) patients treated with 5-fluorouracil (5-FU)-based chemotherapy. Methods. We genotyped 3 EGFR polymorphisms including R497K, G-216T, and the (CA)n repeat, among 499 histologically confirmed CRC patients who had received 5-FU-based chemotherapy after surgery between 1995 and 2001. Survival analyses of EGFR polymorphisms were performed by the log rank test and Kaplan-Meier curves. We used the Cox proportional hazard model to evaluate the association between EGFR genotypes and clinical outcomes. Stratification analysis by gender, tumor stage, and subsite were also carried out. Results. CRC patients with the EGFR (CA)n L/L genotype compared to those with the S/S?S/L genotype had a significantly better overall survival (L, C20 repeats; S,\20 repeats) (hazard ratio (HR) 0.74; 95 % confidence interval (CI) 0.57-0.95), particularly for patients who were male (HR 0.63; 95 % CI 0.44-0.90), who had stage IV disease (HR 0.70; 95 % CI 0.49-0.99), and who had rectal cancer (HR 0.62; 95 % CI 0.42-0.92). Better survival was prominent among patients with the combined genotypes of EGFR (CA)n L/L, G-216T G/G, and R497K K/K (HR 0.51; 95 % CI 0.30-0.87), compared to those with the most common genotypes of the EGFR (CA)n S allele, G-216T G/G, and R497K R allele. Conclusions. EGFR polymorphisms can serve as prognostic predictors for CRC patients receiving 5-FU-based chemotherapy.

KW - Colorectal Neoplasms

KW - genetic polymorphism

KW - survival rate

KW - Colorectal Neoplasms

KW - genetic polymorphism

KW - survival rate

UR - http://www.scopus.com/inward/record.url?scp=84892782781&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892782781&partnerID=8YFLogxK

U2 - 10.1245/s10434-013-3069-4

DO - 10.1245/s10434-013-3069-4

M3 - Article

VL - 20

SP - S599-S606

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

SN - 1068-9265

IS - 3 SUPPL.

ER -